Autopsy report · NCT03838692

Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

“Closed by sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Antonio Fojo

Sponsor type

University, hospital or other

Conditions

Medullary Thyroid Cancer

Interventions

Ponatinib

Participants

0

Trials that died the same way

• Leptin in Human Energy and Neuroendocrine Homeostasis
  “Closed by sponsor. Lack of funding.” (81% match in meaning)
• LCI Apheresis to Obtain Plasma or White Blood Cells
  “Closed by the Sponsor/DSMB/IRB” (80% match in meaning)
• A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
  “Sponsor Decision to close study” (77% match in meaning)
• ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
  “Sponsor has decided to close study.” (75% match in meaning)
• Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
  “Closed by sponsor, lack of enrollment.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.